Holen Sie sich die Stockscreener-App
166.75
0.59%
-0.99
Handel nachbörslich:
166.75
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$167.74
Offen:
$167.86
24-Stunden-Volumen:
193.97K
Relative Volume:
0.94
Marktkapitalisierung:
$3.27B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
66.43
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
+3.12%
1M Leistung:
+23.38%
6M Leistung:
+44.48%
1J Leistung:
+61.66%
1-Tages-Spanne:
$166.07
$169.49
1-Wochen-Bereich:
$160.80
$169.49
52-Wochen-Spanne:
$93.58
$169.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
166.75 | 3.27B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Is Ligand Pharmaceuticals Incorporated stock poised for growthPortfolio Risk Summary & Real-Time Market Trend Scan - Newser
Is Ligand Pharmaceuticals Incorporated stock bottoming outJuly 2025 Final Week & Real-Time Stock Price Movement Reports - Newser
Using data models to predict Ligand Pharmaceuticals Incorporated stock movement2025 Biggest Moves & Precise Entry and Exit Recommendations - Newser
Published on: 2025-09-05 14:36:20 - Newser
What is Ligand Pharmaceuticals Incorporated s revenue forecastMarket Growth Review & AI Powered Trade Plan Recommendations - خودرو بانک
Advanced analytics toolkit walkthrough for Ligand Pharmaceuticals IncorporatedJuly 2025 Movers & Smart Swing Trading Techniques - Newser
Can Ligand Pharmaceuticals Incorporated reach all time highs this yearWeekly Risk Report & AI Forecasted Stock Moves - خودرو بانک
Can Ligand Pharmaceuticals Incorporated withstand a market correctionRisk Management & Intraday High Probability Alerts - خودرو بانک
Published on: 2025-09-05 01:53:48 - Newser
Will Ligand Pharmaceuticals Incorporated see short term momentum2025 Market Outlook & Weekly High Momentum Picks - Newser
What is Ligand Pharmaceuticals Incorporated’s TAM (Total Addressable Market)2025 Buyback Activity & Reliable Entry Point Trade Alerts - خودرو بانک
Is Ligand Pharmaceuticals Incorporated part of any major index2025 Performance Recap & Long-Term Safe Investment Plans - خودرو بانک
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Is this a good reentry point in Ligand Pharmaceuticals IncorporatedTrade Analysis Report & Low Drawdown Investment Strategies - Newser
How to build a dashboard for Ligand Pharmaceuticals Incorporated stockJuly 2025 Analyst Calls & Community Trade Idea Sharing Platform - Newser
Ligand Pharmaceuticals (LGND) director Kozarich sells $76k in stock - Investing.com
Ligand Pharmaceuticals (LGND) director Kozarich sells $76k in stock By Investing.com - Investing.com UK
Ligand Pharmaceuticals Director Sells 467 Shares Between $161.51 and $164.25/Share - AInvest
Volume spikes in Ligand Pharmaceuticals Incorporated stock – what they meanEntry Point & Real-Time Buy Signal Alerts - Newser
Published on: 2025-09-04 06:48:32 - Newser
Custom watchlist performance reports with Ligand Pharmaceuticals Incorporated2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - Newser
Will Ligand Pharmaceuticals Incorporated continue its uptrendPortfolio Update Summary & Community Consensus Trade Alerts - Newser
Will Ligand Pharmaceuticals Incorporated outperform the market in YEAREarnings Growth Report & Weekly High Potential Stock Alerts - خودرو بانک
Using Python tools to backtest Ligand Pharmaceuticals Incorporated strategiesShare Buyback & Scalable Portfolio Growth Ideas - Newser
Oppenheimer Raises Ligand Pharmaceuticals (LGND) Price Target to $190 | LGND Stock News - GuruFocus
Real time pattern detection on Ligand Pharmaceuticals Incorporated stockWeekly Market Outlook & Accurate Technical Buy Alerts - Newser
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $190 From $167, Maintains Outperform Rating - MarketScreener
Can volume confirm reversal in Ligand Pharmaceuticals Incorporated2025 Support & Resistance & Verified Short-Term Trading Plans - Newser
Custom strategy builders for tracking Ligand Pharmaceuticals IncorporatedJuly 2025 Volume & Comprehensive Market Scan Reports - Newser
Will earnings trigger a reversal in Ligand Pharmaceuticals Incorporated2025 Price Action Summary & Consistent Profit Focused Trading Strategies - Newser
Aug Levels: What is the next catalyst for Ligand Pharmaceuticals IncorporatedQuarterly Market Summary & Risk Adjusted Buy/Sell Alerts - خودرو بانک
Benchmark Reaffirms Buy Rating on Ligand with Raised PT to $175. - AInvest
Ligand price target raised to $175 from $160 at Benchmark - TipRanks
Applying Wyckoff theory to Ligand Pharmaceuticals Incorporated stockMarket Rally & Weekly Market Pulse Updates - Newser
Is Ligand Pharmaceuticals Incorporated attractive for institutional investorsLong Setup & Short-Term Trading Opportunity Alerts - خودرو بانک
Can Ligand Pharmaceuticals Incorporated rally from current levelsProduct Launch & Short-Term Trading Opportunity Alerts - Newser
Heatmap analysis for Ligand Pharmaceuticals Incorporated and competitorsJuly 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):